Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913672 | 0.87 | DRD1 (0.44) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| Lithium SCHEMBL29926457 | 0.86 | DRD1 (0.43) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| SCHEMBL21113562 | 0.86 | DRD1 (0.43) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| SCHEMBL6419741 | 0.79 | DRD1 (0.40) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| SCHEMBL7238863 | 0.79 | AKR1C3 (0.41) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| SCHEMBL30915985 | 0.78 | MAOA (0.48) | DRD1DRD4DRD3ALDH1A1ADRA2A | |
| SCHEMBL8142884 | 0.76 | CYP2C19 (0.44) | DRD1DRD4DRD3CYP2C19ABCB11 | |
| SCHEMBL13097997 | 0.76 | HDAC6 (0.30) | — | |
| SCHEMBL29927269 | 0.72 | — | — | |
| SCHEMBL28921395 | 0.71 | DRD4 (0.47) | DRD1DRD4DRD3CYP2C19ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | claimed |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2012-12-27 | — | — | US | claimed |
| EP-2516447-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2012-10-31 | — | — | EP | claimed |
| WO-2011077174-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYÓGYSZERGYÁR NYILÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2011-06-30 | — | — | WO | claimed |
| US-20100261908-A1 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-14 | — | — | US | claimed |
| EP-2205611-A2 | PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS | Dr. Reddy's Laboratories Ltd. (IN) | 2010-07-14 | — | — | EP | claimed |
| WO-2009062044-A2 | PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | claimed |
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| EP-2588483-A1 | IMPROVED PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2013-05-08 | — | — | EP | disclosed |
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20100261908-A1 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-14 | — | — | US | disclosed |
| EP-2205611-A2 | PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS | Dr. Reddy's Laboratories Ltd. (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009062044-A2 | PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009062044-A2 | PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | CYP3A5, CYP2C19, CYP4B1 | DRD1 3248/4885DRD4 2028/4885DRD3 3472/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | DRD1 1081/4885DRD4 2105/4885DRD3 2620/4885 |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | CYP3A5, CYP4B1, P2RY6 | DRD1 4192/4885DRD4 2270/4885DRD3 3723/4885 |
| US-20100261908-A1 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS | PFKP, CYP2C19, CYP2C9 | DRD1 3680/4885DRD4 2734/4885DRD3 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.